Lynx1 Capital Management’s Cymabay Therapeutics CBAY Stock Holding History

Lynx1 Capital Management’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-994,161	Closed	-$14.8M	–	18
2023 Q3	$14.8M	Sell	994,161 -210,889	-18%	-$2.8M	9.8%	4
2023 Q2	$13.2M	Sell	1,205,050 -164,877	-12%	-$1.54M	8.65%	4
2023 Q1	$11.9M	Sell	1,369,927 -283,568	-17%	-$2.27M	9.96%	5
2022 Q4	$10.4M	Sell	1,653,495 -672,338	-29%	-$2.56M	8.97%	5
2022 Q3	$8.14M	Sell	2,325,833 -263,846	-10%	-$948K	7.34%	5
2022 Q2	$7.64M	Buy	2,589,679 +1,201,174	+87%	+$2.87M	6.51%	5
2022 Q1	$4.32M	Buy	1,388,505 +163,537	+13%	+$515K	4.01%	8
2021 Q4	$4.14M	Buy	+1,224,968	New	+$4.65M	3.61%	8

Other funds holding CBAY

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Lynx1 Capital Management's CBAY Position: Q4 2023 in Review

Lynx1 Capital Management sold out of Cymabay Therapeutics (CBAY) in Q4 2023, closing a stake of 994,161 shares — an estimated $14.8M sold.

Lynx1 Capital Management first reported a position in CBAY in Q4 2021 and held it in 8 quarters. The position peaked at $14.8M in Q3 2023. 200 funds tracked by Wall St. Rank hold CBAY as of Q4 2023.

Lynx1 Capital Management reported no remaining Cymabay Therapeutics position as of Q4 2023 after selling out during the quarter.
Lynx1 Capital Management sold 994,161 Cymabay Therapeutics shares in Q4 2023, an estimated $14.8M.
Lynx1 Capital Management first reported a position in Cymabay Therapeutics in Q4 2021 and held it in 8 quarters.
Lynx1 Capital Management's Cymabay Therapeutics position peaked at $14.8M in Q3 2023.
200 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q4 2023.

Based on Lynx1 Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.